Eli Lilly and Company

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Michael Philip Mazanetz

Andrew Caerwyn Williams

Karin Briner

Maria Angeles Martinez-Grau

Roger Ryan Rothhaar

Anne Marie Camp

Georg Dahmann

Matthias Hoffmann

Guenter Linz

Gerhard Schaenzle

Andreas Schnapp

John Gordon Allen

Sandra Handschuh

Edward Walker

Dennis Fiegen

Frantz Victor

Christopher Stanley Galka

Jasna Klicic

Deyi Zhang

Michael Philip Cohen

Matthew Robert Reinhard

Richard Edmund Rathmell

Manuel Javier Cases-Thomas

Selma Sapmaz

Sarah Lynne Hellman

Robert John Scott

John M Schaus

Michael J Rodriguez

Peter Thaddeus Gallagher

Sandra Ann Filla

Barry P Clark

Patrick Gianpietro Spinazze

Stephen East

Maria Ann Whatton

Natalia Pokrovskaia

Michael Wade Tidwell

Richard C Hoying

Marta Maria Pineiro-Nunez

John Cunningham O'Toole

Alicia Marcos Llorente

Valentina O Badescu

Stephen Peter East

Alan Cornell

Karen Briner

Marta Adeva Bartolome

Stephen P East

John Mehnert Schaus

Barry Peter Clark

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein wherein n is either 0 or 1,

Substituted naphthyridines and their use as medicaments

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is &#x2014;NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification. 

[object Object]

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where Ris &#x2014;C&#x2261;C&#x2014;R, &#x2014;CH&#x2550;CRR, or &#x2014;(C-C)alkyl-Aroptionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification. 

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently &#x2014;C(H)&#x2550; or &#x2014;N&#x2550;, provided that at least one of A and B is &#x2014;N&#x2550;, n is 1-3, m is 0-3, and R1-4 are as defined herein.

2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: 

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: Ris selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification. 

Growing community of inventors

Abingdon, United Kingdom

Michael Philip Mazanetz